Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FBL8 CRISPR/Cas9 KO Plasmid (h): sc-406696
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FBL8 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FBL8 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FBL8 Antibody (D-1): sc-390582
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FBL8 CRISPR/Cas9 KO Plasmid (h) | sc-406696 | 20 µg | $397.00 |
Overview
FBXL8 (FBL8) encodes an F-box protein that is predicted to function as a substrate-recognition component of SCF (SKP1–CUL1–F-box) E3 ubiquitin ligase complexes, supporting ubiquitin-dependent protein turnover. Through selective ubiquitination of client proteins, FBXL8 is positioned to influence proteostasis programs that shape cell-cycle progression, signal transduction, and stress responses. Perturbation of F-box–mediated ubiquitin ligase activity can alter checkpoint control and pathway dynamics linked to oncogenic transformation and other proliferative disorders. FBXL8 therefore serves as a useful node for investigating how targeted degradation interfaces with cellular homeostasis and disease-associated signaling networks.
FBL8 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FBXL8 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FBXL8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FBXL8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FBL8 protein expression.
This CRISPR knockout system enables efficient generation of FBXL8-deficient cell models for investigation of FBL8 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FBXL8 exon(s) critical for FBL8 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FBXL8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FBL8 CRISPR/Cas9 KO Plasmid (h) and FBL8 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FBXL8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FBL8 HDR Plasmid (h) and FBL8 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FBXL8 homology arms to support homology-directed repair at defined FBXL8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.